How much funding has ARMO BioSciences raised?

ARMO BioSciences has raised $167.0M in total funding, most recently a Series C round.

Who are ARMO BioSciences's investors?

ARMO BioSciences's investors include Qiming VP, Kleiner Perkins, OrbiMed, DAG Ventures, Eli Lilly, Decheng Capital.

When was ARMO BioSciences founded?

ARMO BioSciences was founded in 2011.

Where is ARMO BioSciences headquartered?

ARMO BioSciences is headquartered in Redwood City, California, United States.

What industry is ARMO BioSciences in?

ARMO BioSciences operates in Biotech, Therapeutics.

How many employees does ARMO BioSciences have?

ARMO BioSciences has 11-50 employees.

ARMO BioSciences

Closed

Immune system activation for cancer treatment

Redwood City, United States · Founded 2011 · $167.0M raised

Biotech

Therapeutics

Headquarters: Redwood City, California
Employees: 11–50
Founded: 2011
Business Model: B2B

Website: lilly.com
Total Funding: $167.0M
Last Round: $67.0M Series CAug 2017
Rounds: 4

About

ARMO BioSciences was a late-stage immuno-oncology biotech company developing a pipeline of novel proprietary product candidates, including pegilodecakin (AM0010), to activate the immune system for treating solid tumors and cancers. The company was acquired by Eli Lilly in 2020 for $1.6 billion.

Summary

ARMO BioSciences is a Biotech company based in Redwood City, United States, founded in 2011. It has raised $167.0M in total across 4 rounds, most recently a $67.0M Series C round in Aug 2017. Investors include Qiming VP, Kleiner Perkins and OrbiMed.